Paul van der Horst has been our Chief Business Officer since May 2021 and was our Chief Financial Officer between May 2024 and November 2024. Prior to joining AgomAb, he was Head of Corporate Development at Galapagos NV (Nasdaq: GLPG), or Galapagos, from April 2019 to April 2021. From March 2016 to March 2019, he was the Director of Business Development at Galapagos and from March 2016 to September 2018 he was the Investor Relations Officer Europe at Galapagos. Earlier in his career, he worked at boutique investment bank, Kempen & Co., in Amsterdam. From January 2020 to April 2021 he was a nonexecutive Board Member of Fibrocor Therapeutics (Toronto, Canada). In addition, from April 2021 to January 2023, Dr. van der Horst was an advisor at ImmuneTune in the Netherlands and, since January 2022, was a member, and as of June 2023 became president, of the Supervisory Board of Molecure S.A. in Poland. Dr. van der Horst studied medicine and holds a Ph.D. in Gynaecology from the Erasmus University Medical Centre in Rotterdam, The Netherlands.